Predictors of Recurrence and Overall Survival in Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy and Surgery: A Comprehensive Statistical Analysis.

Treatment protocols revealed a borderline significant difference ( p = 0.05).

also in 2,000 other papers

Regarding the diagnostic group, patients with primary tumors without axillary involvement showed a trend toward reduced recurrence risk (OR = 0.19, 95% CI: 0.03–1.47, p = 0.070), consistent with the expectation that localized disease has a more favorable prognosis.

also in 13,339 other papers

Nonetheless, our analysis suggests a possible trend towards increased recurrence in Luminal B1 tumors (37.21% in the recurrence group vs. 24.71%, p = 0.51), warranting further investigation into its clinical implications [ 27 ].

also in 276 other papers

However, a slight trend can be observed, with patients receiving platinum/taxane-based treatments showing slightly lower recurrence rates compared to those treated with anthracycline-based regimens.

also in 977 other papers

The results indicate that platinum/taxane-based regimens (including biologics) were associated with a lower recurrence risk compared to anthracycline-based treatments (OR = 0.15, 95% CI: 0.01–0.78, p = 0.070), though this did not reach statistical significance.

also in 24,045 other papers